Eli Lilly and Co reported a 7.2 percent rise in quarterly revenue, lifted by higher demand for its diabetes drug Trulicity and other new treatments.
The drugmaker said net income rose to $771.8 million, or 73 cents per share, in the fourth quarter ended Dec. 31, from $478.4 million, or 45 cents per share, a year earlier.
Revenue rose to $5.76 billion from $5.38 billion.
Latest posts by supriya kashyap (see all)
- Natco’s partner Alvogen gets nod for influenza drug in US - November 6, 2017
- USFDA moves to more efficient global pharmaceutical manufacturing inspections - November 6, 2017
- Sanofi refines expectations on drop in sales at diabetes arm - November 6, 2017